Study on the Safety and Tolerability of CFT7455 for Patients with Relapsed or Hard-to-Treat Non-Hodgkin's Lymphoma or Multiple Myeloma

Inclusion Criteria

• Be willing and able to provide signed consent to participate.
• Be 18 years or older.
• Have a performance status score of 2 or less, indicating the ability to carry out daily activities with some limitations.
• Have a confirmed diagnosis of NHL or MM that has returned or is not responding to previous treatments, and not be eligible for other beneficial treatments or have refused them.
• For MM patients:
  • Have measurable disease at the start of the study.
  • Have received at least 3 prior treatments, including specific drugs like lenalidomide and a proteasome inhibitor.
  • Have disease that is resistant to or has progressed shortly after the last treatment.
• For NHL patients:
  • Have a documented diagnosis and measurable disease.
  • Have received specific prior therapies depending on the type of NHL.
• Provide a tumor tissue sample for analysis.
• Have adequate organ function based on specific blood tests.
• Women must not be pregnant or breastfeeding and must use effective contraception if of childbearing potential.
• Men must use a condom during intercourse with women of childbearing potential and refrain from donating sperm during and after treatment.
• Refrain from donating blood during and after treatment.

Exclusion Criteria

• Have disease affecting the central nervous system.
• Have received radiation therapy within 2 weeks before starting the study.
• Have active lung inflammation (pneumonitis).
• Have certain types of blood cancers or conditions like plasma cell leukemia or amyloidosis.
• Have received a specific drug, CC92480, in the most recent treatment.
• Have significant nerve damage or heart problems.
• Have had a blood clot within 3 months before starting the study.
• Have another cancer that has progressed or required treatment in the past 3 years.
• Have had major surgery within 2 weeks before starting the study.
• Have significant side effects from previous cancer treatments.
• Have received a live vaccine within 4 weeks before starting the study.
• Have a history of HIV or active hepatitis B or C infections.
• Have an uncontrolled infection or serious medical condition.
• Be taking certain medications that affect how the study drug works.
• Be participating in another clinical trial or have used an investigational treatment recently.
• Have difficulty swallowing pills or have a condition affecting digestion.
• Have a psychiatric or substance abuse disorder that would interfere with the study.
• Have an allergy to the study drug or its ingredients.